GlassScriptPhysician profile
Elizabeth Smith Harding
NPI 1467962290
$2,885.13
in general payments reported to CMS, 2019-2025
21 companies · $686 in 2025
The $686 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $517 · 2023: $734 · 2024: $568 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.11 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.09 | 2021-2025 | |
| Janssen Biotech, INC. | $323.96 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $241.22 | 2023-2025 | |
| Galderma Laboratories, L.P. | $223.45 | 2021-2025 | Dysport, Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $210.19 | 2021-2025 | Dupixent |
| Pfizer INC. | $200.04 | 2021-2024 | |
| Merz North America, INC. | $199.93 | 2022-2023 | Xeomin |
| Lilly USA, LLC | $135.60 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Biofrontera INC. | $128.17 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $110.67 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $107.21 | 2023-2025 | |
| Leo Pharma INC. | $105.03 | 2024 | Adbry |
| Incyte Corporation | $97.09 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $53.81 | 2023-2025 | Sotyktu |
| Journey Medical Corporation | $51.17 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $49.72 | 2022-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.96 | 2022-2025 | Cabtreo |
| Amgen INC. | $27.46 | 2022 | |
| Organon LLC | $20.23 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.43 | 2021 | |
| Botanix Sb INC | $16.70 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.